Year: 2021
Type: Article
Title: Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience
Author: Trajkova, Sanja
Author: Stojanovska, Simona
Author: Ridova, Nevenka
Author: Krstevska balkanov, Svetlana
Author: Pivkova Veljanovska, Aleksandra
Author: Cevreska, Lidija
Author: Popova-Labacevska, Marija
Author: Panovska Stavridis, Irina
Abstract: Introduction: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the Severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with COVID-19 infection, including development of several autoimmune events that suggests that infection with SARS CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders. Aim: Review the hematological autoimmune phenomenon after infection with SARS-COV-2 in order to assist into the pathogenic mechanisms, clinical manifestations and treatment of this group of patients. Materials and methods: This is a retrospective study that includes 21 patients with autoimmune diseases like secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia( AIHA) and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology for a period of time from January 2020 to April 2021. Results: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic auto-immune presentations was 18,4 ± 10,3 days. The therapy of this conditions in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events. Conclusion: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patients.
Publisher: Scientific Foundation SPIROSKI
Relation: Open Access Macedonian Journal of Medical Sciences
Identifier: oai:repository.ukim.mk:20.500.12188/15283
Identifier: http://hdl.handle.net/20.500.12188/15283Identifier: 10.3889/oamjms.2021.6766
Identifier: https://oamjms.eu/index.php/mjms/article/download/6766/6047Identifier: https://oamjms.eu/index.php/mjms/article/download/6766/6047Identifier: 9
Identifier: B
Identifier: 940
Identifier: 944
